Compare ACM Research Inc (ACMR) vs Mesoblast Limited (MESO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Mesoblast Limited — how do they compare? ACM Research Inc trades at $97.79 (market cap $6.54B), while Mesoblast Limited trades at $14.52 (market cap $1.82B). The key difference: ACM Research Inc is far larger — about 3.6× Mesoblast Limited's market cap, and ACM Research Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| ACMR | MESO | |
|---|---|---|
Market Cap | $6.54B | $1.82B |
Sector | Technology | Technology |
52-Week High | $126.89 | $20.96 |
52-Week Low | $23.92 | $10.45 |
Enterprise Value | $5.61B | $1.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
MESO trades at $14.33, down 0.35% with a bearish technical signal. The company reported Q1 2025 revenue of $17.20M with a gross margin of 80.52% but significant losses (-$102.14M net income). Recent developments include FDA BLA filing for rexlemestrocel-L in heart failure and a $50M debt facility draw. Analyst consensus shows 45% buy ratings amid high valuation multiples (P/S 30.52).
Outlook hinges on regulatory approvals and commercial execution. The stock offers speculative upside from pipeline catalysts but carries substantial risk from cash burn and clinical trial outcomes. Investors face volatility from binary regulatory events while current fundamentals reflect pre-revenue biotech challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
